BIOGEN INC. News
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
see moreBIOGEN INC. Market News
6d
Biogen Out of Nasdaq-100: What Investors Must Know
- Biogen’s recent removal from the Nasdaq‑100, combined with volatile January trading and an upcoming Feb. 6 earnings report, creates near-term catalysts and headwinds for BIIB. This article explains the index impact, trading implications, and what to watch next.
13d
Biogen Gains: EU Spinraza Approval; Feb 6 Earnings
Biogen (BIIB) earned European approval for a high-dose Spinraza regimen on Jan 12, 2026—an outcome that could strengthen its SMA franchise in Europe. With quarterly results due Feb 6 and recent volatile share moves, investors are watching revenue cadence, guidance, and uptake of the new dosing to judge near-term upside.
20d
Biogen Stock Slides After JP Morgan Week Outflows.
Biogen (BIIB) saw modest share weakness amid broad biotech fund outflows following the J.P. Morgan Healthcare Conference. With analysts largely neutral, lower passive demand after Nasdaq‑100 exclusion, and fresh Alzheimer’s competition highlighted by Novartis’s $1.7B SciNeuro deal, near‑term upside appears limited absent a clear pipeline or corporate catalyst.
27d
Biogen Rally: CHMP OKs High‑Dose Nusinersen Surge!
Biogen stock jumped to a 52-week high after the EMA's CHMP issued a positive opinion for a high-dose nusinersen regimen. The regulatory catalyst, combined with strong trading days in early January, has driven measurable investor interest and could expand Spinraza’s EU positioning pending the European Commission decision.
01 Jan at 00:37
Biogen: CHMP Nod for Nusinersen; LEQEMBI Wins Data
Biogen received a positive CHMP opinion for a high-dose nusinersen regimen and reported CTAD data strengthening LEQEMBI’s pharmacodynamic profile. Both developments offer near-term regulatory and scientific catalysts for BIIB shares, though analyst coverage and upside remain modest.
25 Dec at 00:38
Biogen Dropped from Nasdaq-100; HSBC Downgrade Now
Biogen was removed from the Nasdaq‑100 and received an HSBC downgrade last week, triggering index-driven selling, reduced liquidity, and renewed analyst scrutiny. This article explains the immediate market mechanics, investor implications, and key items to watch next for BIIB.
18 Dec at 00:37
Biogen Removed From Nasdaq-100; ETF Selloff Looms
Biogen (BIIB) will be dropped from the Nasdaq‑100 before trading on Dec. 22, 2025, triggering likely passive selling by index-tracking funds. Recent volume spikes and price weakness contrast with improved technical momentum and a reduced competitive overhang after a rival Alzheimer’s candidate failed Phase 3.